Research programme: mesenchymal stromal cell therapy - Orbsen Therapeutics

Drug Profile

Research programme: mesenchymal stromal cell therapy - Orbsen Therapeutics

Alternative Names: CD362+ stem cell therapy; CD362+SSC; Cyndacel-M; Cyndecel; ORB1+ MSC; ORB1+ SSC; Orbcel-C

Latest Information Update: 01 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orbsen Therapeutics
  • Developer Orbsen Therapeutics; Regenerative Medicine Institute
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic foot ulcer
  • No development reported Adult respiratory distress syndrome

Most Recent Events

  • 02 May 2017 European Union and University of Birmingham plans a phase I/II MERLIN trial for Primary sclerosing cholangitis & Hepatitis in United Kingdom (NCT02997878)
  • 29 Apr 2017 Pharmacodynamics data from a preclinical trial presented at the 2017 American Transplant Congress (ATC-2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Adult-respiratory-distress-syndrome in Ireland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top